Latest Strategic Collaborations News

Amaero Ltd reports a remarkable 445% increase in quarterly revenue driven by powder sales and manufacturing scale-up, alongside securing a US$22.8 million loan and exclusive supply agreements with key defense and aerospace players.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

AdAlta Limited has raised up to A$1.1 million through a private placement, boosting its war chest to advance innovative cellular immunotherapy projects targeting solid cancers.

Metal Powder Works Limited (MPW) has landed a $1 million contract with the US Navy for its innovative expeditionary DirectPowder™ unit, while expanding its alloy portfolio and customer base amid a $15 million capital raise.

Locksley Resources has produced the first 100% American made antimony ingot in decades, validating a fully domestic mine-to-metal supply chain and advancing U.S. critical minerals independence.

Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.

Archer Materials has entered a strategic collaboration with Emergence Quantum to fast-track the development of graphene-based quantum devices, aiming to bridge cutting-edge science with commercial applications.

Ionic Rare Earths has expanded its capital raising to $15.6 million, driven by a $3 million strategic investment from US firm Argentem Creek Partners and strong shareholder support. The funds will accelerate projects across magnet recycling, rare earth refining, and US supply chain development.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.

Weebit Nano has successfully taped out embedded ReRAM test chips at onsemi’s 65nm BCD fab, marking a critical step toward commercialising its low-power memory technology in automotive and AI markets.